Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
GALN On Other Exchanges
Symbol
Exchange
OTC US
SIX Swiss Ex
Frankfurt
OTC US
All times are local (Market data is delayed by at least 15 minutes).

galenica ag-reg (GALN) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
6.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALENICA AG-REG (GALN)

Related News

No related news articles were found.

galenica ag-reg (GALN) Related Businessweek News

No Related Businessweek News Found

galenica ag-reg (GALN) Details

Galenica Ltd. engages in the development, manufacture, and distribution of pharmaceutical products in Switzerland and internationally. It operates through two business units, Vifor Pharma and Galenica Santé. The company offers iron replacement products, including Ferinject/Injectafer, Venofer, Maltofer, and Velphoro; immuno-stimulant products, such as Broncho-Vaxom and Uro-Vaxom; infectious diseases/OTX products, over-the-counter products, and herbal remedies; and synthetic and biotech drugs for use in immunology and the treatment of infectious diseases. It also markets products manufactured by third parties; provides products for patients suffering from chronic kidney disease; and develops and markets CellCept for various applications involving auto-immune diseases. In addition, the company offers pre-wholesale logistics services, including storage and distribution of products, and debt collection services to pharmaceutical and healthcare companies; supplies healthcare products to pharmacies, physicians, drug stores, care homes, and hospitals; and handles and coordinates product purchasing, sales, warehousing, and distribution of products for third parties. Further, it operates approximately 318 own pharmacies and 173 partner pharmacies under the Amavita and Sun Store brands in Switzerland; a chain of 61 own pharmacies in partnership under the Coop Vitality brand; MediService specialty pharmacy that offers medication for the treatment of patients in their own homes; and 161 Winconcept partner pharmacies. Additionally, the company provides master data systems for the healthcare market; publishes printed and electronic technical information on pharmaceutical products; maintains databases; offers management solutions under Triamun brand; TriaPharm total management software solution for pharmacies; TriaOne non-sector specific ERP solution for retail; and TriaMed software for physicians. Galenica Ltd. was founded in 1927 and is headquartered in Bern, Switzerland.

6,238 Employees
Last Reported Date: 08/11/15
Founded in 1927

galenica ag-reg (GALN) Top Compensated Officers

Executive Chairman, Chairman of Governane & N...
Total Annual Compensation: SFr.3.8M
Compensation as of Fiscal Year 2014.

galenica ag-reg (GALN) Key Developments

Galenica AG Announces Earnings Results for the First Six Months Ended June 30, 2015

Galenica AG announced earnings results for the first six months ended June 30, 2015. For the six months, the company's net profit attributable to shareholders was CHF 130.81 million, or CHF 20.17 per diluted share, compared to CHF 134.64 million, or CHF 20.76 per diluted share, for the same period ended June 30, 2014. Operating income was CHF 1.86 billion, compared to CHF 1.81 billion for the same period ended June 30, 2014.

Galenica Ltd., H1 2015 Earnings Call, Aug 11, 2015

Galenica Ltd., H1 2015 Earnings Call, Aug 11, 2015

Galenica AG Announces Earnings Results for the First Half Ended June 2015; Revises Earnings Guidance for the Full Year 2015

Galenica AG announced earnings results for the first half ended June 2015. Net profit in the six months through June advanced 5.5% to CHF 157.8 million. Earnings before interest and tax (EBIT) grew 6.2% to CHF 200.8 million. Net sales increased almost 8% to CHF 1.79 billion. The company raised its 2015 full-year profit forecast, prompted by the strong first-half performance of the Vifor Pharma unit. The company now expects to book its 20th consecutive increase in profit, both before and after deduction of minority interests. Previously, the company was targeting a flat net profit in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALN:SW SFr.0.00 CHF 0.00

GALN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $82.27 USD -1.12
Celesio AG €24.87 EUR -0.112
McKesson Corp $197.58 USD -3.22
UDG Healthcare PLC 504.50 GBp +1.50
Walgreens Boots Alliance Inc $86.55 USD -0.87
View Industry Companies
 

Industry Analysis

GALN

Industry Average

Valuation GALN Industry Range
Price/Earnings 27.7x
Price/Sales 2.1x
Price/Book 4.7x
Price/Cash Flow 21.7x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENICA AG-REG, please visit www.galenica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.